BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 24369188)

  • 21. Serum levels of prostate-specific antigen and vitamin D in peritoneal dialysis patients.
    Passadakis P; Ersoy F; Tam P; Memmos D; Siamopoulos K; Ozener C; Akçiçek F; Camsari T; Ates K; Ataman R; Vlachojannis J; Dombros N; Utas C; Akpolat T; Bozfakioglu S; Wu GG; Karayaylali I; Arinsoy T; Stathakis C; Yavuz M; Tsakiris D; Dimitriades A; Yilmaz ME; Gültekin M; Karayalçin B; Challa A; Polat N; Oreopoulos DG
    Adv Perit Dial; 2004; 20():203-8. PubMed ID: 15384827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does obesity affect the accuracy of prostate-specific antigen (PSA) for predicting prostate cancer among men undergoing prostate biopsy.
    Oh JJ; Jeong SJ; Lee BK; Jeong CW; Byun SS; Hong SK; Lee SE
    BJU Int; 2013 Aug; 112(4):E265-71. PubMed ID: 23432960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic efficacy of free prostate-specific antigen/total prostate-specific antigen ratio for the diagnosis of prostate cancer in low concentration (≤4 ng/ml) and intermediate levels of total prostate-specific antigen (4.01-10.0 ng/ml).
    Caliskan S
    J Cancer Res Ther; 2017; 13(2):279-283. PubMed ID: 28643748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The patients less than 50 years: is there a need to lower the PSA cutoff point?
    Hekal IA
    Prostate Cancer Prostatic Dis; 2009; 12(2):148-51. PubMed ID: 18825164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
    Dell'Atti L
    J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Retropubic adenomectomy in patients with a high level of prostate-specific antigen after prostatic biopsy].
    Veliev EI; Kotov SV; Golubtsova EN; Sokolov AE; Bogdanov AB; Avakian AIu
    Urologiia; 2012; (1):59-63. PubMed ID: 22646005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA.
    Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M
    Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acquired renal cystic disease and tumor markers in chronic hemodialysis patients.
    Polenakovic M; Sikole A; Dzikova S; Polenakovic B; Gelev S
    Int J Artif Organs; 1997 Feb; 20(2):96-100. PubMed ID: 9093887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimum PSA reflex-range.
    Benecchi L
    Arch Ital Urol Androl; 2006 Jun; 78(2):44-8. PubMed ID: 16929601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
    Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum tumor markers in hemodialysis patients.
    Maoujoud O; El Machtani S; Asseraji M; Atbib Y; Zajjari Y; Taoufik A; Elbouaiti E; Zouhair O; Benyahia M; Tellal S
    Int J Artif Organs; 2014 Feb; 37(2):126-32. PubMed ID: 24619900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of prostate-specific antigen after tamsulosin treatment in patients with elevated prostate-specific antigen and lower urinary tract symptoms associated with low incidence of prostate cancer at biopsy.
    Tubaro A; De Nunzio C; Mariani S; Trucchi A; Miano R; Vicentini C; Miano L
    Urology; 2010 Aug; 76(2):436-41. PubMed ID: 20538320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of hemodialysis on prostate-specific antigen.
    Monath JR; Burkart JM; Freedman BI; Pittaway DE; Russell GB; Assimos DG
    Urology; 1993 Oct; 42(4):398-400. PubMed ID: 7692660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
    Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A
    BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T1c prostate cancer detection rate and pathologic characteristics: comparison between patients with serum prostate-specific antigen range of 3.0 to 4.0 ng/mL and 4.1 to 10.0 ng/mL in Korean population.
    Park HK; Hong SK; Byun SS; Lee SE
    Urology; 2006 Jul; 68(1):85-8. PubMed ID: 16806412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
    Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Body mass index and prostate specific antigen levels in Jamaican men.
    Tulloch-Reid MK; Aiken WD; Morrison BF; Tulloch T; Mayhew R; Wan RL; Bennett FI; Coard KC; Jackson MD
    West Indian Med J; 2011 Jun; 60(3):316-21. PubMed ID: 22224345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.